Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 5/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24920359 | 0.81 | ROCK2 (0.36) | ROCK2NR1H2SCDELANEGPR119 | |
| SCHEMBL141413 | 0.78 | FFAR1 (0.52) | ROCK2NR1H2SCDGSK3BUSP30 | |
| SCHEMBL23360896 | 0.77 | FFAR1 (0.40) | ROCK2NR1H2SCDUSP30 | |
| SCHEMBL23349424 | 0.76 | SCD (0.38) | ROCK2NR1H2SCDELANEUSP30 | |
| SCHEMBL19964091 | 0.74 | FFAR1 (0.40) | ROCK2NR1H2SCDELANEUSP30 | |
| SCHEMBL25826104 | 0.74 | FFAR1 (0.44) | ROCK2NR1H2SCDUSP30 | |
| SCHEMBL19341509 | 0.74 | FFAR1 (0.44) | ROCK2NR1H2SCDUSP30 | |
| SCHEMBL1206008 | 0.73 | ROCK2 (0.45) | ROCK2NR1H2SCDELANEGPR119 | |
| SCHEMBL25045768 | 0.73 | ROCK2 (0.44) | ROCK2NR1H2SCDELANEGPR119 | |
| SCHEMBL30350813 | 0.73 | ROCK2 (0.36) | ROCK2NR1H2SCDELANEUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | ROCK2 3234/4885NR1H2 265/4885SCD 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.